Virscio
About Virscio
We are a team of experienced scientists and innovators, passionate about helping to solve significant human health challenges through biomedical research. From preclinical proof-of concept to IND-enabling studies, Virscio’s goal is to bring clarity and confidence to R&D investment decision making and improve the odds of clinical translation. We fully support critical development stages, spanning preclinical strategy, protocol design, in-life study execution, sample processing, data analysis, study reporting and defining regulatory path, with a focus on in vivo primate efficacy and safety, pharmacokinetics, pharmacodynamics and therapeutic delivery. Our capabilities are enabled by broad experience, including:
- 30+ years of translational R&D experience
- 145+ team with exceptional retention, many having decades of experience
- 12+ MD and/or PhD Study Directors
- 500+ industry preclinical study / program engagements
- 30+ models validated and applied to therapeutic program development
- Significant engagement with large pharma, venture-backed, and academic clients from around the world
Virscio is seeking experienced, creative, and highly motivated individuals with the ability to lead and contribute to multidisciplinary R&D initiatives supported by leading biotechnology and pharmaceutical companies.
10 articles about Virscio
-
Virscio Announces Launch of Pathology and Tissue Pharmacodynamics Services Division
3/8/2023
Virscio accelerates investment in advanced histology capabilities to complement in vivo translational R&D service strength
-
Virscio Publishes Data Validating Non-Human Primate Model for Testing Chronic Retinal Neovascularization and Vascular Leakage Drug Candidates
4/27/2020
Virscio, a translational research company providing definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced publication of data that validate a nonhuman primate (NHP) model for testing drug candidates targeting retinal ischemic and neovascular diseases
-
RxGen to Present Alzheimer’s Disease APP/Abeta Cellular and Animal Models at the Society for Neuroscience’s 49th Annual Meeting
10/14/2019
One of the primary challenges in drug development is the inability of preclinical models to reliably predict clinical outcomes.
-
RxGen, Inc. Signs On As LabCentral Gold Sponsor
12/8/2016
-
RxGen, Inc. And ProLynx Present Data On Ocular Delivery Platform
5/13/2014
-
Iris Pharma and RxGen, Inc. Announce Strategic Alliance
4/19/2012
-
RxGen, Inc. and miRagen Therapeutics Announce Award of National Institutes of Health (NIH)-National Heart, Lung, and Blood Institute SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease
8/25/2011
-
RxGen, Inc. and Santaris Pharma A/S Use LNA-antimiR Technology to Antagonize the Liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol
3/27/2008
-
RxGen PrimaTox, Inc And BioTrove, Inc. Announce Collaboration
1/27/2006
-
RxGen, Inc. Announces The Formation Of RxGen PrimaTox, Inc., A Subsidiary Focused On Molecular Toxicology In Primates And Humans, Spencer Farr Named CEO
1/26/2006